We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+14.31%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$16.1B
AUM Growth
+$2.04B
Cap. Flow
-$98.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
35.04%
Holding
1,426
New
99
Increased
660
Reduced
349
Closed
106

Top Buys

Rank Stock Value
1
IRM icon
Iron Mountain
IRM
+$97M
2
VICI icon
VICI Properties
VICI
+$80.3M
3
ESS icon
Essex Property Trust
ESS
+$78.8M
4
WPC icon
W.P. Carey
WPC
+$61.7M
5
IBN icon
ICICI Bank
IBN
+$28M

Sector Composition

Rank Sector Weight
1 Real Estate 52.1%
2 Technology 13.53%
3 Consumer Discretionary 4.91%
4 Financials 4.82%
5 Healthcare 4.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMLX icon
1201
Amylyx Pharmaceuticals
AMLX
$2.15B
$4K ﹤0.01%
266
ANIP icon
1202
ANI Pharmaceuticals
ANIP
$1.84B
$4K ﹤0.01%
70
AUTL
1203
Autolus Therapeutics
AUTL
$378M
$4K ﹤0.01%
+575
New +$2.19K
BCRX icon
1204
BioCryst Pharmaceuticals
BCRX
$2.44B
$4K ﹤0.01%
692
CABA icon
1205
Cabaletta Bio
CABA
$430M
$4K ﹤0.01%
+175
New +$2.94K
COLL icon
1206
Collegium Pharmaceutical
COLL
$1.18B
$4K ﹤0.01%
127
DAWN
1207
DELISTED
Day One Biopharmaceuticals
DAWN
$4K ﹤0.01%
296
DBC icon
1208
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
$4K ﹤0.01%
200
INVA icon
1209
Innoviva
INVA
$1.6B
$4K ﹤0.01%
260
KROS icon
1210
Keros Therapeutics
KROS
$197M
$4K ﹤0.01%
111
LGND icon
1211
Ligand Pharmaceuticals
LGND
$5.8B
$4K ﹤0.01%
63
MIRM icon
1212
Mirum Pharmaceuticals
MIRM
$6.58B
$4K ﹤0.01%
148
MNKD icon
1213
MannKind Corp
MNKD
$1.2B
$4K ﹤0.01%
1,058
PLRX icon
1214
Pliant Therapeutics
PLRX
$65.6M
$4K ﹤0.01%
196
PRME icon
1215
Prime Medicine
PRME
$535M
$4K ﹤0.01%
+398
New +$3.07K
PTGX icon
1216
Protagonist Therapeutics
PTGX
$8.66B
$4K ﹤0.01%
163
SRRK icon
1217
Scholar Rock
SRRK
$5.9B
$4K ﹤0.01%
208
TNGX icon
1218
Tango Therapeutics
TNGX
$4.14B
$4K ﹤0.01%
355
MORF
1219
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4K ﹤0.01%
155
DCPH
1220
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4K ﹤0.01%
272
AMAM
1221
DELISTED
Ambrx Biopharma Inc
AMAM
$4K ﹤0.01%
+258
New +$2.93K
ADPT icon
1222
Adaptive Biotechnologies
ADPT
$3.5B
$3K ﹤0.01%
530
ARCT icon
1223
Arcturus Therapeutics
ARCT
$160M
$3K ﹤0.01%
90
AVDL
1224
DELISTED
Avadel Pharmaceuticals
AVDL
$3K ﹤0.01%
245
AVXL icon
1225
Anavex Life Sciences
AVXL
$232M
$3K ﹤0.01%
314

Similar funds

Daiwa Securities Group's Q4 2023 Portfolio in Review

As of Q4 2023, Daiwa Securities Group held 1,426 positions worth $16.1B, up 15% from $14B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Daiwa Securities Group's Q4 2023 filing shows 99 new, 660 increased, 349 reduced and 106 closed positions. Its largest new stake was Veralto: 45,224 shares worth $3.72M. The largest sale was Mid-America Apartment Communities, an estimated $128M.

By sector, the portfolio is most concentrated in Real Estate at 52% of assets, down from 53% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2023 buy was Veralto: 45,224 shares worth $3.72M.
  • Daiwa Securities Group added most to Iron Mountain in Q4 2023, an estimated $97M increase.
  • Daiwa Securities Group's biggest Q4 2023 reduction was Mid-America Apartment Communities, cutting an estimated $128M.
  • Daiwa Securities Group fully exited Activision Blizzard in Q4 2023, selling an estimated $6.04M.
  • Daiwa Securities Group's ten largest holdings make up 35% of its $16.1B portfolio in Q4 2023.
  • Daiwa Securities Group opened 99 new positions and closed 106 in Q4 2023.
  • Daiwa Securities Group's portfolio value rose 15% quarter-over-quarter to $16.1B.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.